Macquarie Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Macquarie Group’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-519	Closed	-$68K	–	2512
2020 Q4	$68K	Hold	519	–	–	﹤0.01%	1965
2020 Q3	$26K	Hold	519	–	–	﹤0.01%	2116
2020 Q2	$25K	Buy	+519	New	+$24.1K	﹤0.01%	2128
2019 Q3	–	Sell	-411	Closed	-$13K	–	1953
2019 Q2	$13K	Buy	+411	New	+$11.1K	﹤0.01%	1791

Macquarie Group's EIDX Position: Q1 2021 in Review

Macquarie Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 519 shares — an estimated $68K sold.

Macquarie Group first reported a position in EIDX in Q2 2019 and held it in 4 quarters. The position peaked at $68K in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Macquarie Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Macquarie Group sold 519 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $68K.
Macquarie Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 4 quarters.
Macquarie Group's Eidos Therapeutics, Inc. Common Stock position peaked at $68K in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Macquarie Group's 13F filing for Q1 2021, filed 14 May 2021.